No news on BNC375 is not surprising given what Bell Potter flagged to the market in March
*DJ Bionomics Price Target Cut 14% to A$0.38/Share by Bell Potter
[Dow Jones] Bell Potter sees Aussie drug developer Bionomics and U.S. partner Merckcarrying out an additional Phase 1 trial under their Alpha7 Alzheimer's program, andthat's an encouraging step. "It bodes well for Bionomics/Merck's long-term collaborationand gives us confidence around Merck's intention to move the drug into Phase 2," the bullsays. The trial is expected to start recruiting between March and June, with completionin early 4Q. Still, the extra work will mean Bionomics won't get an estimated US$20million payment for the drug moving into Phase 2 trials so soon. Bell Potter now seesthat milestone payment happening in the first half of 2020, a year later than before. Dow Jones Newswires March 14, 2019
BNO Price at posting:
13.0¢ Sentiment: Buy Disclosure: Not Held
